Array BioPharma (Nasdaq: ARRY) today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study ...

* Array Biopharma -on December 22, 2016 entered into loan and security agreement providing for revolving line of credit of up to $5 million * Array Biopharma Inc - loan agreement also provides for ...

Clinical trial results from Array BioPharma's (Nasdaq: ARRY) wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical ...

Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: Normally ...

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Array BioPharma ...

BOSTON (CBS.MW) -- Shares of Array BioPharma jumped 16 percent in after-hours trading on Monday after the small biotech firm said it'll collaborate with Genentech on research into potential new cancer ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The Boulder drug company lands a late-stage drug from Swiss ...